We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+85.72%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$73.2M
Cap. Flow
-$340M
Cap. Flow %
-27.05%
Top 10 Hldgs %
36.58%
Holding
220
New
69
Increased
26
Reduced
46
Closed
56

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.6M
2
GOSS icon
Gossamer Bio
GOSS
+$8.85M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.61M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.3M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$6.53M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$23.1M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
3
IMVT icon
Immunovant
IMVT
+$12M
4
ARGX icon
argenx
ARGX
+$11.4M
5
VSTM icon
Verastem
VSTM
+$7.36M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$13.7M 1.09%
507,559
-41,900
-8% -$1.16M
NVAX icon
27
PUT
Novavax
NVAX
$1.21B
$13.7M 1.09%
+164,300
New +$6.28M
KALV
28
DELISTED
KalVista Pharmaceuticals
KALV
$13.5M 1.07%
1,113,395
+166,790
+18% +$1.77M
CRSP icon
29
PUT
CRISPR Therapeutics
CRSP
$4.69B
$13.2M 1.05%
179,100
– –
RETA
30
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$13.1M 1.04%
83,700
-41,300
-33% -$6.28M
SBBP
31
DELISTED
Strongbridge Biopharma plc.
SBBP
$12.4M 0.98%
3,271,238
-121,549
-4% -$364K
ZGNX
32
PUT
DELISTED
Zogenix, Inc.
ZGNX
$11.9M 0.94%
439,300
-310,100
-41% -$8.55M
ITCI
33
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.8M 0.94%
+459,300
New +$9.3M
CRBP icon
34
PUT
Corbus Pharmaceuticals
CRBP
$165M
$11.3M 0.9%
+45,000
New +$9.09M
MPT
35
PUT
Medical Properties Trust
MPT
$2.84B
$11.3M 0.9%
+600,000
New +$10.6M
SCPH
36
DELISTED
scPharmaceuticals
SCPH
$10.8M 0.86%
1,468,647
+395,000
+37% +$3.47M
BPMC
37
CALL
DELISTED
Blueprint Medicines
BPMC
$10M 0.8%
128,400
+78,400
+157% +$5.3M
ACAD icon
38
PUT
Acadia Pharmaceuticals
ACAD
$4.51B
$9.69M 0.77%
200,000
-40,000
-17% -$1.92M
ARDX icon
39
Ardelyx
ARDX
$1.24B
$9.64M 0.77%
1,392,565
-69,669
-5% -$484K
MDGL icon
40
CALL
Madrigal Pharmaceuticals
MDGL
$12.6B
$9.59M 0.76%
+84,700
New +$8.33M
SAGE
41
CALL
DELISTED
Sage Therapeutics
SAGE
$9.53M 0.76%
229,300
+75,000
+49% +$2.72M
CVM icon
42
PUT
CEL-SCI Corp
CVM
$19.9M
$9.51M 0.76%
21,257
+4,590
+28% +$1.88M
STSA
43
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$9.46M 0.75%
+328,824
New +$7.61M
XLE icon
44
PUT
State Street Energy Select Sector SPDR ETF
XLE
$39B
$9.2M 0.73%
+486,200
New +$9.04M
GOSS icon
45
Gossamer Bio
GOSS
$101M
$9.15M 0.73%
+703,999
New +$8.85M
CRBP icon
46
CALL
Corbus Pharmaceuticals
CRBP
$165M
$8.39M 0.67%
+33,333
New +$6.74M
SAGE
47
DELISTED
Sage Therapeutics
SAGE
$8.36M 0.67%
201,151
+18,100
+10% +$657K
KYNB
48
CALL
Kyntra Bio
KYNB
$27.4M
$8.11M 0.65%
8,000
– –
BTAI icon
49
CALL
BioXcel Therapeutics
BTAI
$24.8M
$7.89M 0.63%
9,300
+2,844
+44% +$1.85M
KDNY
50
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$7.79M 0.62%
673,995
-53,605
-7% -$739K
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Ikarian Capital held 220 positions worth $1.26B, down 5.5% from $1.33B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital withdrew a net $340M in Q2 2020, closing 56 positions and reducing 46 holdings. Its most notable exit was Acceleron Pharma, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 20% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Blueprint Medicines worth $15.7M.

  • Ikarian Capital's largest Q2 2020 buy was Blueprint Medicines: 201,662 shares worth $15.7M.
  • Ikarian Capital added most to bluebird bio in Q2 2020, an estimated $5.73M increase.
  • Ikarian Capital's biggest Q2 2020 reduction was BioXcel Therapeutics, cutting an estimated $17.3M.
  • Ikarian Capital fully exited Acceleron Pharma in Q2 2020, selling an estimated $23.1M.
  • Ikarian Capital's ten largest holdings make up 37% of its $1.26B portfolio in Q2 2020.
  • Ikarian Capital opened 69 new positions and closed 56 in Q2 2020.
  • Ikarian Capital's portfolio value fell 5.5% quarter-over-quarter to $1.26B.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.